





Objective: To present an integrative review of literature on the effects of gluten on gastrointestinal symptoms in individuals who do not have celiac disease.
Background: Despite a rapid increase in the number of people who identify as “gluten free,” the prevalence of celiac disease has remained roughly the same. Previous literature testing the effect of gluten on gastrointestinal symptoms has not been conclusive.
Public Health Significance: Many people believe that being “gluten free” is healthier, when in fact gluten-free products often contain more fats and sugars and cost more financially. This diet trend poses a risk on the health of our population.
Data Sources: The electronic databases of PubMed and OVID were used to identify studies using the key words “gluten free diet,” “irritable bowl syndrome,” and “non-celiac gluten sensitivity.”
Study Selection: Using exclusion and inclusion criteria 427 articles’ titles and abstracts were scanned for relevance to adhering to a gluten free diet and specifically addresses patients with non-celiac gluten sensitivity. Further review of references produced four articles. Thirteen articles were read in full. Six studies fully met inclusion and exclusion criteria for full in-depth review. 
Data Synthesis: Based on their findings, studies were either categorized as concluding no significant effect of gluten or significant effects of gluten on gastrointestinal symptoms.
Conclusions: Substantially larger, multi-center research studies need to be conducted in order to truly understand the impact of gluten, if any, on gastrointestinal symptoms in non-celiac disease individuals. While some of the studies conclude there are significant detrimental effects as a result of consuming gluten, other studies conclude no significant changes in symptoms.
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Table 1. Gluten Products









Table 2. Gluten Free Products




Annie’s Macaroni & Cheese	3.00	260	4	400	50	7
Bisquick Baking Mix	4.41	140	0.5	340	31	2

The highest driving factor in being “gluten free” is the misconception that this diet is healthier. People need to differentiate between eating gluten free products compared to following to a gluten free lifestyle (e.g., limiting pastas and bread, increasing fruits and vegetables).
1.1	Purpose
The purpose of this integrated review was to summarize the existing literature related to the effects of gluten on gastrointestinal symptoms in people who do not have celiac disease. By using these in-depth studies, these integrative review adds insight to the “gluten-free” trend our society is experiencing today in order to confirm the benefits of the general population adhering to a gluten free diet or express concern when following this popular diet. 
1.2	Chapter Summaries
This paper begins by defining celiac disease, the common onsets for this illness, as well as the diet restrictions individuals with this diagnoses must adhere to. Furthermore, the background section of this paper explains what gluten is and how it can cause damage to the small intestine of a person who has been clinically diagnosed with celiac disease. Due to the increase in the general population self identifying as gluten free, it is important to address where non celiac gluten sensitivity derives from and why today’s society measures a higher percentage of people self identifying as following a gluten free diet than ever before. 
The methods section explains the process for identifying relevant articles for this integrative review, using keywords and scanning references of included articles. The result section of this paper breaks down the six included articles into two statistical results and provides an overview of each research project and statistical results. Two of the articles analyzed in this review concluded that there were no statistically significant effects of gluten on gastrointestinal symptoms. The remaining four articles found a significant effect, an increase, in self-reported gastrointestinal symptoms after participants consumed gluten. 
The final sections of this paper discuss the importance and limitations of the current literature available on measuring the effect of gluten on people who do not have celiac disease. From these limitations, this paper proposes future research endeavors.  The increased level of arsenic and mercury in gluten free foods pose a significant risk and thus is the public health significance of this paper. While the articles included in this review may find contradicting statistical results, all provide unique insight on the effect of gluten on gastrointestinal symptoms.   
2.0 	BACKGROUND
Despite the small percentage of people who actually have celiac disease and must adhere to a gluten free diet, today’s society continues to see an increase in the number of people identifying as “gluten free.” Rutgers New Jersey Medical School (Doheny, 2016) suggested that people who do not have celiac disease may instead have non-celiac gluten sensitivity, thus choosing not to eat food containing gluten. Peter H.R. Green, MD, the director of the Celiac Disease Center at Columbia University instead credits the increase in Americans who identify as being gluten free to “it’s a trendy diet” (Doheny, 2016). 
2.1	What is gluten?
Gluten is protein commonly found in barley, wheat, and rye. The two main proteins in gluten are gliadin and glutenin, which help food, especially breads, hold their shape and improve taste (Bjarnadottir, 2017).
2.1.1	What is celiac disease?
Celiac disease is a genetic autoimmune disorder in which the body attacks the small intestine after a person consumes gluten. If a person with celiac disease consumes gluten, they may not only suffer from symptoms such as diarrhea and bloating but also potential long-term or permanent damage to the villi in the small intestine. If damage occurs, the body is unable to properly absorb nutrients, which may cause malnutrition. According to the World Gastroenterology Organization, about 1% of the population worldwide had a clinical diagnosis of celiac disease (WGO, 2016). 
2.1.2	What causes celiac disease?
In many cases, celiac disease is triggered over time by an immune response from the affected person consuming gluten. A person will experience damage to their small intestine and often times exhibit many of the common symptoms attributable to celiac disease (Mayo 2018). Adhering to a gluten free diet is the best option to reduce and prevent further damage to the small intestine for a person with celiac disease, since there is no cure. Mayo Clinic reports that:
Celiac disease occurs from an interaction between genes, eating foods with gluten and other environmental factors, but the precise cause isn’t known. Infant feeding practices, gastrointestinal infections and gut bacteria might contribute to developing celiac disease. Sometimes celiac disease is triggered – or becomes active for the first time – after surgery, pregnancy, childbirth, viral infection or severe emotional stress. When the body's immune system overreacts to gluten in food, the reaction damages the tiny, hair-like projections (villi) that line the small intestine. Villi absorb vitamins, minerals and other nutrients from the food you eat. If your villi are damaged, you can't get enough nutrients, no matter how much you eat. Some gene variations appear to increase the risk of developing the disease. But having those gene variants doesn't mean you'll get celiac disease, which suggests that additional factors must be involved (Mayo 2018, p. 4).
While there is no known cause of celiac disease, there are many risk factors. Celiac disease is more common in people who have a family history of celiac disease, have Down syndrome, autoimmune thyroid disease, or type 1 diabetes (Mayo 2018).
2.1.3	What are the negative outcomes of celiac disease?
Untreated celiac disease or not adhering to a gluten free diet may cause irreversible damage to the small intestine as well as contribute to other medical conditions. The main concern is malnutrition, due to the body’s inability to properly absorb nutrients if there is damage to the small intestine. Malnutrition and malabsorption can also contribute to other medical conditions such as loss of bone density, increased risk of miscarriage and infertility, and cancer (Mayo, 2018). 
2.2	Non Celiac Gluten Sensitivity (NCGS)
Some people in the general population report relief of gastrointestinal symptoms when they avoid food that contains gluten. For example, people with irritable bowel syndrome (IBS) often experience symptoms of diarrhea, constipation, and abdominal pain (Mayo, 2018).  IBS is a disorder that affects the large intestine, but adhering to a gluten free diet is not medically necessary. People who report an increase in gastrointestinal symptoms due to gluten consumption are often referred to having non- celiac gluten sensitivity (NCGS).
2.3	Why is there an increase in identifying as “gluten-free?”
In 2015, it was estimated that one in five people electively chose to eliminate gluten from their diet (Doheny, 2016). Hyun-Seok Kim, MD, from Rutgers University found that most commonly, people who identified as gluten free were Caucasian, women, and ages 20 to 39. Additionally, Kim reported that many people believe that following a gluten-free diet is healthier. 
3.0 	METHODS
For this integrative review, Pubmed and Ovid Medline electronic databases were searched to identify relevant articles addressing the impact of gluten on gastrointestinal symptoms in individuals who not have celiac disease. Using the following search terms: gluten free diet, irritable bowl syndrome, and non-celiac gluten sensitivity. The search was limited to articles published between 2007 and 2017, articles available in English, and studies that were original research. Titles were scanned for relevant articles and abstracts of potentially relevant titles. Full articles were then abstracted and read in their entirety if their abstracts met inclusion criteria. I also reviewed reference lists and the “similar” feature of PubMed to identify additional articles to include in the review. 
	From the database search review, 17,948 articles were initially identified, 427 title and abstracts were scanned, and 13 articles were read in full for potential eligibility. Seven of the articles were excluded and six articles were included for the integrative review. 
4.0 	RESULTS
A total of six articles were reviewed. Articles excluded from this review did not fit inclusion criteria measuring the effects of gluten on the symptoms of their study participants. Studies with additional variables (Fructan, for example) or those that relied on participants’ ability to correctly identify the placebo and the testing group were excluded for this review. All articles chosen for review were examined in detail for relevance to adhering to a strict gluten free diet with a challenge as well as requiring participants to write down their gastrointestinal symptoms. 
4.1	No gluten effect
In a study (Biesiekierski et al. 2011) in Melbourne, Australia, researchers used a double blind placebo controlled trial in order to test the effect, if any, of gluten consumption on gastrointestinal symptoms. Study participants were people who did not have celiac disease, were over 16 old, met the Rome III criteria for IBS, and also self-reported that their symptoms improved on a gluten-free diet. The participants were instructed to follow a strict gluten-free diet for six weeks prior to the start of the study. They kept a food diary during the study to track and rank their symptoms. At the end of the six weeks, participants received “study food” which either contained gluten or was gluten free. The researchers noted that participants were not able to identify any differences between the gluten free bread and muffins compared to the food containing gluten.
This study (Biesiekierski et al. 2011) did not find any statistically significant results, and the authors reported that they ended the study early due to lacking the necessary number of participants to achieve an 80% power and a statistically significant p-value in order to analyze all of their data. Furthermore, the authors attributed their difficulty in recruiting participants to the difficulty of diagnosing celiac disease. Since there are no distinguishing biomarkers for celiac disease, the researchers noted that they did not have the ability to rule out celiac disease for all of their participants; if individuals did not have a specific clinical diagnosis of no celiac disease they were not enrolled. 
Overall, these authors found no significant difference between their two study groups for the categories on which they ran analysis. This study measured certain biomarkers at baseline and after treatment in order to discover a difference after. The researchers concluded that there were no significant differences in the biomarkers measured. Despite not finding a significant result, the authors did report their extremely low number of participants, which potentially has an impact on these results as well.
In a re-challenge study (Biesiekierski et al. 2013) in Melbourne, Australia, researchers used a double blind crossover trial in order to test the effects of fermentable, poorly absorbed, short-chain carbohydrates (FODMAPs) in study participants with NCGS. Similar to the first study, this one recruited through advertisements and additionally through referrals from gastroenterology clinics, in order to increase the response rate. This study used the same inclusion criteria as the previous study: over 16 years old, met Rome III criteria for IBS symptoms, which are self-reported feeling better with a gluten free diet, as well as strictly following a gluten free diet for six weeks before the study began. 
The first phase of this study began with a one-week baseline period during which study participants recorded a daily food diary with their typical diet and self-reported symptoms. Following this, all participants received education on adhering to a diet low in FODMAPs. Participants were then randomly assigned to receive one of three treatments for one week: high-gluten, low-gluten, or placebo. All of the study food was prepared by the research staff and delivered weekly to each participant. After this, there was a minimum two-week washout period before crossing over to the next treatment group. Some participants withdrew from the study before completing all of the treatment groups due to intolerable symptoms. The researchers did allow some participants to end a specific treatment group early when they complained of excruciating gastrointestinal pain and still continue on to the next treatment group
For the re-challenge phase, participants were again randomly assigned to one of the three treatment groups, but this time for only three days. They took a minimum of a three-day washout period before crossing over to the next treatment group. When comparing the overall symptoms across treatment groups, the researchers found no significant differences when comparing baseline to after the challenge (p > .209). Overall, this re-challenge study found no significant effect of gluten in participants with NCGS who adhere to a low FODMAP diet.
4.2	Gluten Effect
In an Italian study (Elli et al. 2016), researchers used a double blind placebo controlled cross over design to test the effect of a gluten free diet on individuals with NCGS. Researchers enrolled 140 participants with suspected NCGS, who were over 18 years old and whose symptoms met the Rome III criteria. Unlike studies mentioned above, this study did not enroll individuals who had IBS. The first phase of this study began with participants adhering to a strict gluten free diet for three weeks. At the end of this time, the participants completed questionnaires about their symptoms, and those who had an improvement in their symptoms when following a gluten free diet continued on in the study. The participants were either given capsules containing gluten or the placebo capsule, which contained rice starch. Participants took these capsules for seven days, followed by a seven-day washout period, and then crossed over to the other group for seven days. 
Participants completed questionnaires about their symptoms at the end of each seven-day time period. After the gluten challenge, researchers analyzed the participants’ reports of their symptoms and stated that while participants were consuming gluten they experienced “a greater deterioration of their well-being” (Elli et al. 2016, p. 7) than compared to consuming the placebo (p = 0.05).
In another study (Carroccio et al. 2012) in Italy, the researchers first used a retrospective study design to review medical charts to identify patients presenting with clinical IBS at either the Department of Internal Medicine at the University Hospital of Palermo or the Department of Internal Medicine of the Hospital of Sciacca. These patients became the study controls. In the next phase, the participants adhered to a strict elimination diet for four weeks and kept a self-reported food diary and symptom report. Not only did participants eliminate wheat, but they were also asked to exclude cow’s milk, eggs, tomato, and chocolate from their diet. These are foods that commonly contribute to increased gastrointestinal symptoms. Finally, the researchers conducted a double blind placebo controlled trial. The study participants ingested either a wheat capsule or a placebo capsule for two weeks, followed by a one-week washout period, and then took the other capsule for another two weeks.
Participants reported significantly more symptoms during the consumption of the wheat capsule compared to their baseline of gastrointestinal symptoms after the first week, after the second week, as well as analyzing both weeks together (p < 0.0001). Additionally, this study found a significant increase in symptoms during the two weeks of wheat containing capsules compared to the two weeks of placebo capsules (p<0.0001). 
In a third study (Di Sabatino et al. 2015) based in Italy, different researchers conducted a double blind randomized placebo-controlled cross-over trial in order to calculate the effects, if any, of gluten on study participants with suspected NCGS. Participants were enrolled in the study through referrals from two Italian celiac centers, one in Pavia and one in Bologna. The study took place over a five-week period and participants completed a questionnaire on their intestinal and extraintestinal symptoms every day. Participants noted intestinal symptoms on a scale of 0, absent to 3, severe and included issues such as diarrhea, abdominal pain or bloating, and nausea. The extraintestinal symptoms included things such as a headache, tiredness, and foggy mind, with a scale of 0, absent or 1, present. 
Week 1 began with participants adhering to a strict gluten free diet. Week 2 was the first round of randomization, in which participants received capsule containing either wheat gluten or rice starch. Week 3 was the washout period before the participants crossed over to the other group for week 4. The study ended after the second washout period in week 5. 
These researchers found an overall significant increase in both intestinal symptoms (p < 0.0001) and extraintestinal symptoms (p < 0.0001) when participants ingested gluten compared to the placebo. Related to intestinal symptoms, the participants experienced a significant increase in abdominal bloating (p = .040) and abdominal pain (p = .047) when consuming gluten. Participants also experienced a significant increase in the following extraintestinal symptoms when consuming gluten: Aphthous stomatitis (p = .025), depression (p = .025), and foggy mind (p = .019). Even with a small amount of gluten being ingested, participants still had a significant increase in symptoms compared to receiving the placebo (Di Sabatino et al. 2015).
In an Iranian study (Shahbazkhani et al. 2015), researchers used a double blind randomized placebo controlled trial to determine the effects of adhering to a gluten free diet for patients with IBS. Participants were recruited from Imam Khomeini hospital in Iran, were at least 16 years old, and had a clinical IBS diagnosis meeting the Rome III criteria. They were randomly assigned to receive gluten or gluten-free powder to mix into water. Participants consumed 100g of powder per day for a total of six weeks. Participants also completed questionnaires to report their symptoms. This study found a significant increase in overall symptoms in participants in the gluten group compared to the placebo group (p = .0001). This study did not find a significant difference when comparing individual symptoms, such as bloating (p = .3) and nausea (p =0.6), between the two study groups.

5.0 	DISCUSSION
In the United States, approximately 3.1 million people adhere to a gluten free diet (McCarthy, 2017). Among these people though, 72% chose to follow this food restriction without a medical necessity. This diet trend began because many people believe that adhering to a gluten-free diet is healthier. Following a gluten free diet is indeed healthier if making conscious food decisions to increase fresh fruit and decrease processed foods, but many people choose gluten free products in exchange for gluten containing products, like pasta or pretzels, which have a higher fat content and cost more (Blazer, 2013).
The purpose of this integrative review was to identify the effects of gluten, if any, by looking at gastrointestinal symptoms. The six studies included in this review produced one of two results: either no significant effects of gluten on gastrointestinal symptoms or significant, worsening symptoms after participants consumed gluten. The conflicting results from the current literature raise questions about why we see these different results. The public health field must also ask questions about the importance and necessity of the gluten-free diet, especially in people who do not have celiac disease. Even though a gluten-free diet is necessary for some medical conditions, society must weight the benefits and consequences if the general population consumes gluten-free products. 
This integrative review found only two different statistical results from the studies analyzed, which raises the question of how and why the researchers found different effects. First, each study had a different method for how and when the participants reported their gastrointestinal symptoms. All of the studies included in this review is based on participant self-report of symptoms; for  most studies participants kept a daily log of their symptoms but the Italian study (Elli et al. 2016) did not have the participants record their symptoms until the end of each study week. This could mean that, because recording some of the most important data occurred several days later, there might be recall bias. The participants may not accurately remember their symptoms or may under-or over-report their symptoms depending on if they believe they are in the gluten-free group or if they were in the gluten group. Having participants record their symptoms each day decreases the potential for this kind of bias. 
Second, many of the studies, in both the control and study groups, report an increase of abdominal pain and bloating. While this may be attributable to gluten consumption, Italian researchers (Di Sabatino et al. 2015) point out that these are symptoms the general public typically complains about on a daily basis. Furthermore, these same researchers admitted that in their own study very few symptoms, both intestinal and extraintestinal, had a significant difference when ingesting gluten by themselves, and they found a significant increase only when all of the symptoms were analyzed together when comparing gluten and the placebo. 
This paper proposes that the washout period between treatment groups could potentially contribute to significant or non significant results. Despite finding different results, both Elli et al.’s and Di Sabatino et al.’s groups had the same washout period of only seven days between treatment groups. Furthermore, there are no significant differences in the order of treatment, starting with gluten or starting with placebo (Di Sabatino et al. 2015). 
Lastly, some of the studies included in this integrative review provided their participants with study food, while other studies educated their participants on how to properly read food labels and provided their participants with a list of acceptable and non-acceptable gluten-free food. Additionally, there is always the potential that participants did not adhere to a gluten free diet, despite being instructed to.
5.1	Implications for future research
Future research is needed in order to measure and compare the dose and effect of gluten. In one of the studies (Elli et al. 2016) that found no significant effect of gluten on gastrointestinal symptoms, participants consumed 5.6 grams of gluten per day. In comparison, one of the studies (Di Sabatino et al. 2015) that did find a significant effect of gluten on gastrointestinal symptoms, participants consumed only 4.375 grams of gluten per day. This amount is roughly equal to two slices of white bread. While the study that did not find any significant results had 98 participants who underwent the gluten challenge, the study that showed a significant increase in gastrointestinal symptoms included only 59 participants who underwent the entire study. While the number of participants is different as well as the amounts of gluten, are other factors contributing to why these studies are concluding different results? 
	Studies looking at the effect of gluten on gastrointestinal symptoms are limited in the literatures. Among these, the results are conflicting. Furthermore, many of the studies have a very small sample size. Multi-center research studies with a much larger number of participants are needed in order to successfully test the significance of gluten in people who do not have celiac disease. Researchers could test the effect of specific doses of gluten and could test multiple doses within the study followed by a washout period and then crossover. This would provide insight to the dose specific effects of gluten, if any while also allowing researchers to compare the symptoms reported at each specific dose administered. 
6.0 	PUBLIC HEALTH SIGNIFICANCE
People commonly confuse the healthier choice of living a gluten free lifestyle with exchanging products and consuming common items like pasta and breads in their gluten free form or substituting regular flour with rice flour (Whiteman, 2017). Furthermore, picking rice over pasta may seem as the “better” health conscious choice but the bioaccumulation of arsenic in rice and rice flour poses a risk to the population’s health. In the study (Bulka et al. 2017), The Unintended Consequences of a Gluten-Free Diet, researchers measured almost double the amount of urinary arsenic and higher blood levels of inorganic mercury in participants who were elective gluten-free eaters. Exposure to mercury and arsenic increases the risk of developing cancer and cardiovascular disease (Whiteman, 2017). 
7.0 	CONCLUSION
While some studies conclude that consuming gluten has significant detrimental effects, other studies conclude that no significant changes in gastrointestinal symptoms occur. For people who are clinically diagnosed with celiac disease, adhering to a gluten free diet is essential in order to prevent further permanent damage to their small intestine. If damage continues they face grave medical conditions such as malnutrition, infertility, and an increase in developing small bowl cancer. There are no medical indications that people who do not have celiac disease must adhere to a gluten free diet. Additional research must be conducted in order to determine if there is a dose and effect response to gluten in people who do not have celiac disease. 
APPENDIX A: STUDIES INCLUDED IN INTEGRATIVE REVIEW
Table 3. Articles synthesized by study result
Study result	Author, Year,Location	Study Design	N	Results
No significant effect of gluten on gastrointestinal symptom	Biesiekierski et al, 2011Melbourne, Australia	Double blind randomized placebo controlled trial1/3 response rate to study advertisements	34 participants	No significant differences in biomarkers 
	Biesiekierski et al, 2013Melbourne, Australia	Re-challenge studyDouble blind cross over trial	37 participants for phase I22 participants for re-challenge	No significant findings on the effect of gluten, specific or dose-dependent, in participants with NCGS on a low FODMAP dietNo significant differences in symptoms between treatment groups
(p > .209)
Significant effect of gluten on gastrointestinal symptoms	Elli et al, 2016Italy	Double blind placebo controlled cross over trial5.6g of gluten per day	140 participants enrolled98 underwent challenge	Significant increase of symptoms when consuming gluten, compared to the placebo
	Carroccio et al,2012Italy	Retrospective study to identify study controlsDouble blind placebo controlled challenge	150 controls identified by medical charts920 study participants	
	Di Sabatino et al, 2015Italy	Double blind randomized placebo controlled cross over trial4.375g of gluten per day	61 participants enrolled, 59 completed study	Significant increase of intestinal symptoms during gluten consumption (p < 0.0001)Significant increase of extraintestinal symptoms during gluten consumption (p < 0.0001)
	Shahbazkhani et al, 2015Iran	Double blind randomized placebo controlled trial100g of gluten per day	148 participants enrolled, 72 completed study	Significant increase of symptoms for participants in the gluten group (p = 0.0001)





Figure 1. Diagram of study selection for integrative review
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